KLCC Group CEO Datuk Md Shah Mahmood said the group is exploring this venture without a dedicated time frame for its implementation . “ We are looking at developing a full-fledged sector which will incorporate a hospital , senior living and the infrastructure that comes with it ,” he explained , adding that this will be a big thing for the group and a long-term project .

He said a steady stream of cash flow is ready to be used and whatever projects undertaken by the group would be driven by the market . Md Shah is also the CEO of KLCCP Stapled Group , which comprises KLCC Property Holdings Berhad ( KLCCP ) and KLCC Real Estate Investment Trust ( REIT ).

“ As an established group , there are stringent criteria for acquisition and investments , particularly for the REIT segment . We look at potential and performing assets because the REIT will only acquire these once they mature .”

Until then , the group seeks what can be injected into their portfolio .

“ Overall , our assets amount to RM18bil for KLCCP . Nevertheless , we plan on looking at new spaces that we are not in yet , something we like to call ‘ white spaces ’,” he said .

Md Shah expressed that the group is well off with its most stable office segment as it tripled its net lease for its long-term tenants .

LEADING local genomic sequencing centre , AGTC Genomics , has been recently awarded the Malaysia Technology Excellence Award 2023 for its remarkable innovations in precision diagnostics with the development of liquid biopsy technology .

Signalling a possible tide shift in the field of oncology , this revolutionary method to detect cancer is set to redefine early diagnosis and treatment decision-making .

In the ongoing battle against cancer , time is of the essence . Detection of the disease emerges as a pivotal factor in determining its gravity and the treatment needed . Therefore , the sooner it is detected , the sooner patients get the required treatment . This significantly elevates their survival rates and quality of life and potentially helps patients curb treatment costs .

However , traditional blood tumour markers were strongly scrutinised for their limitations in identifying early-stage cancers , contributing to delayed diagnoses and diminished survival rates .

With the development of the liquid biopsy method , AGTC Genomics now stands at the brink of what could be a new chapter in cancer detection and treatment .

“ Early detection is the cornerstone of cancer survival and treatment . Liquid biopsy is not just another diagnostic tool ; it is the future of early cancer detection ,” stated AGTC Genomics CEO Professor Chee-Onn Leong .

Deep DNA sequencing serves as the groundwork of liquid biopsy , enabling the

Professor Dr Chee-Onn Leong , CEO of AGTC Genomics , processing the samples for a liquid biopsy procedure .

“ We are fully occupied for the office buildings , we also managed to secure more occupancy for our retail , which is Suria KLCC . We currently have about 96 per cent in occupancy for retail .”

The Mandarin Oriental Hotel did very well . “ We ’ re back in the black . The hotel business has been challenging , particularly in the last few years , but we have been pushing for occupancy and a new general manager to drive our business forward .”

He added that the fourth quarter results looked promising for the group as they looked to raise the bar and give out better dividends to shareholders .

He said : “ For us to be better , a good support system must be in place . Ultimately , we are working with customers , so understanding those dynamics is really important . Particularly , providing a good quality customer experience and worth remembering . I believe we have crafted a winning formula already .”

detection of circulating tumour DNA ( ctDNA ) shed by tumours in the bloodstream . This breakthrough offers sensitive and specific detection of early-stage cancers across diverse organs .

Recent findings at the International Congress of Pathology and Laboratory Medicine ( ICPALM2023 ) in September underscore the unmatched potential of multi-cancer early detection ( MCED ) using AGTC Genomics ’ pioneering technology .

In addition , liquid biopsies extend beyond early detection . They stand to play a pivotal role in diagnosis , treatment decision-making , reduction of invasive procedures , and monitoring for recurrence . AGTC Genomics ’ technology increases survival rates and enhances the overall quality of life for cancer survivors .

AGTC Genomics , being the sole Malaysian provider of comprehensive liquid biopsy sequencing of over 500 cancer-related genes , offers a unique alternative to standard detection processes .

A few of the various benefits of this innovative procedure include higher accuracy rates of 83.1 per cent sensitivity and 95.4 per cent specificity , surpassing existing blood tests , as well as a less invasive and straightforward collection process and faster results .

The liquid biopsy results can be integrated with treatment planning , as they utilise novel genomic analysis techniques for detailed insights into cancer biology .

IF YOU are an investor , you might want to buy into Sunway Berhad as a cheaper entry into the impending listing of Sunway Healthcare Group ( SHG ), which may happen sooner rather than later .

Under the shareholders ’ agreement with Singapore ’ s sovereign wealth fund GIC Pte Ltd , the initial public offering ( IPO ) for SHG has to be completed by Oct 2027 .

RHB Research , in making this recommendation , said : “ The strong performance of all the hospitals may help to accelerate the timing of the listing , with SHG ’ s estimated worth at RM9 billion . Similar to the listing of Sunway Construction eight years ago , investors are expected to be rewarded via this value-unlocking exercise , the firm said in its recent note . It raised the target price for Sunway to RM3.00 from RM2.65 .

Benchmarking against the valuation of the disposal of Ramsay Sime Darby Healthcare in November last year , RHB Research said SHG ’ s enterprise value ( EV ) may potentially be worth RM9 billion based on the same 20.1 times EV / earnings before interest tax depreciation and amortisation ( ebitda ) multiple and its financial year 2024 ebitda forecast ( FY24F ) of RM450 million .

Upon the potential listing in FY25F-26F , SHG may have a market capitalisation of RM10-12 billion . Sunway , which currently has a market capitalisation of about RM12 billion has an 84 per cent stake in SHG .

RHB research revised the ebitda for SHG upward by 90 per cent , on the performance of newer hospitals , especially Sunway Medical Centre ( SMC ) Seberang Jaya , which was better than expected . The hospital opened in November 2022 and has been ebitda positive since the second quarter of 2023 .

“ We expect the hospital to start turning profitable at a profit before tax ( PBT ) level in the second half of 2024 . Given the expansion pipeline , SHG is likely to have 2,500 beds by 2027 from the current 1,100 beds ,” RHB Research said .

The firm said that stripping off the valuations of all the listed entities and the estimated value for SHG , Sunway ’ s other divisions are only worth RM1.8 billion . “ This is significantly undervalued , as the investment properties not currently owned by the real estate investment trust ( REIT ) already have a total book value of RM2.6 billion ,” it said .

“ Sunway owns a strategic landbank at Velocity , South Quay , as well as 1,770 acres in Iskandar Malaysia just off the Tuas link , which , in our view , is a jewel given all the catalytic developments and the upcoming establishment of Johor- Singapore special economic zone ,” RHB research added in its note .